Who
Jeffrey Stein
Director
Company insider
Files Form 4 as: Director, IDEAYA Biosciences; President & CEO, Cidara Therapeutics; Director, Paratek Pharmaceuticals; President & CEO, Trius Therapeutics.
In numbers
- Trades disclosed
- 160
- Buys
- 21
- Sells
- 2
- Bought
- $5.9M
- Sold
- $37K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 6 Aug 2010
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | IDYA IDEAYA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IDYA IDEAYA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | IDYA IDEAYA BiosciencesBiotechnology | SEC FORM 4 Bought | $1.6M50,000 at $32.96 | filing |
| 2 Mar 2026filed 2 Mar 2026 | IDYA IDEAYA BiosciencesBiotechnology | SEC FORM 4 Bought | $1.6M50,000 at $32.96 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara TherapeuticsBiotechnology | SEC FORM 4 Code D | $1.3M5,763 at $221.50 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,499 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —27,174 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —51,999 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —560,888 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —275,000 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara TherapeuticsBiotechnology | SEC FORM 4 Code D | $527K2,379 at $221.50 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara TherapeuticsBiotechnology | SEC FORM 4 Code D | $15.0M67,498 at $221.50 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,949 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,749 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,249 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,499 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,249 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,499 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —27,174 | filing |
News
No headline names them, or the companies they trade most, lately.